Upregulated Cellular Expression of IL-17 by CD4+ T-Cells in Osteoporotic Postmenopausal Women
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Aim: The study aimed to investigate cellular expression of IL-17 by CD4+ T-cells in osteoporotic postmenopausal women. Methods: We enrolled 25 postmenopausal women with osteoporosis (PostMO) and 25 postmenopausal women with normal bone mineral density measurements (PostM) to examine the production of IL-17, tumor necrosis factor a (TNFa) and receptor activator of nuclear factor γ-B ligand (RANKL) by CD4+ T-cells and IL-17, RORγt, TNFa and RANKL mRNA levels in CD4+ T-cells. Circulating concentrations of IL-17 along with IL-6, TNFa, RANKL and osteoprotegerin (OPG) were also determined. Results: Osteoporotic postmenopausal women had higher serum concentrations of IL-17 (3.7 ± 1.3 vs. 2.5 ± 1.1 ng/ml, p = 0.042), IL-6 (158 ± 56 vs. 105 ± 39 pg/ml, p = 0.044), TNFa (138 ± 41 vs. 74 ± 11 pg/ml, p < 0.001) and OPG (1.7 ± 0.4 vs. 1.3 ± 0.4 ng/ml, p = 0.039) than healthy controls. The IL-17-producing CD4+ T-cells were higher in the PostMO group than in the PostM group (7.1 ± 2.4 vs. 4.9 ± 1.4%, p = 0.0015). Additionally, osteoporotic postmenopausal women had greater mRNA levels of IL-17 (3.5 ± 2.9 vs. 1.2 ± 1.0%, p = 0.019) and RORγt (5.7 ± 2.5 vs. 2.2 ± 1.0%, p < 0.001) in CD4+ T-cells than in healthy controls. Conclusions: Our findings implied that the upregulated production of IL-17 may play an important role in regulating bone loss in osteoporotic postmenopausal women.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Zhao et al. (2016), who showed that osteoporotic postmenopausal women express increased levels of proinflammatory cytokines (TNF, IL-1, IL-6, or IL-17) when compared to their non-osteoporotic counterparts [20].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [20]
Citations
Cites
Lam, J., Takeshita, S., Barker, J. E., Kanagawa, O., Ross, F. P., & Teitelbaum, S. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11176 · Cited by 1,440
Skeletal remodeling in health and disease
Zaidi, M. (2007) · Nature Medicine · doi:10.1038/nm1593 · Cited by 1,069
Estrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in Osteoclasts
Nakamura, T., Imai, Y., Matsumoto, T., Sato, S., Takeuchi, K., Igarashi, K., Harada, Y., Azuma, Y., Krust, A., Yamamoto, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.025 · Cited by 1,013
Estrogen deficiency and bone loss: an inflammatory tale
Weitzmann, M. N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28550 · Cited by 990
Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α
Cenci, S., Weitzmann, M. N., Roggia, C., Namba, N., Novack, D., Woodring, J., & Pacifici, R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11066 · Cited by 705
Roggia, C., Gao, Y., Cenci, S., Weitzmann, M. N., Toraldo, G., Isaia, G., & Pacifici, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251534698 · Cited by 513
Kurihara, N., Bertolini, D., Suda, T., Akiyama, Y., & Roodman, G. D. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.11.4226 · Cited by 486
Yano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363
Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival
Krum, S. A., Miranda‐Carboni, G. A., Hauschka, P. V., Carroll, J. S., Lane, T. F., Freedman, L. P., & Brown, M. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601984 · Cited by 353
Lubberts, E., van den Bersselaar, L., Oppers-Walgreen, B., Schwarzenberger, P., Coenen-de Roo, C. J. J., Kolls, J. K., Joosten, L. A. B., & van den Berg, W. B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.5.2655 · Cited by 348
Cited by
Li, J., Chen, X., Lu, L., & Yu, X. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.02.003 · Cited by 273
Osteoporosis: Pathophysiology and therapeutic options
Föger‐Samwald, U., Dovjak, P., Azizi-Semrad, U., Kerschan‐Schindl, K., & Pietschmann, P. (2020) · EXCLI journal · doi:10.17179/excli2020-2591 · Cited by 257
“…of proinflammatory cytokines in osteoporosis is strengthened by the findings of elevated levels of TNF, IL-1, IL-6, or IL-17 in the first ten years after menopause (Pacifici et al., 1990) and in osteoporotic postmenopausal women compared to non-osteoporotic postmenopausal women (Zhao et al., 2016).”
BackgroundT-Cell Mediated Inflammation in Postmenopausal Osteoporosis
Wu, D., Cline-Smith, A., Shashkova, E., Perla, A., Katyal, A., & Aurora, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687551 · Cited by 227
Dar, H. Y., Shukla, P., Mishra, P. K., Anupam, R., Mondal, R. K., Tomar, G. B., Sharma, V., & Srivastava, R. K. (2018) · Bone Reports · doi:10.1016/j.bonr.2018.02.001 · Cited by 194
“In humans, estrogen deficiency is associated with an expansion of RANKL and TNF-α expressing T cells (Zhao et al., 2016).”
BackgroundMolecular and Cellular Mechanisms of Osteoporosis
Zhivodernikov, I. V., Kirichenko, T. V., Markina, Y. V., Postnov, A. Y., & Markin, A. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115772 · Cited by 166
“Postmenopausal women with osteoporosis have higher concentrations of serum IL-17A, RANKL, and OPG and more IL-17-producing CD4+ T-cells in the peripheral blood [14,15].”
BackgroundOsteoporosis: Molecular Pathology, Diagnostics, and Therapeutics
Adejuyigbe, B., Kallini, J., Chiou, D., & Kallini, J. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914583 · Cited by 148
“…framework for osteoporosis is further strengthened by studies conducted by Zhao et al. (2016), who showed that osteoporotic post-menopausal women express increased levels of proinflammatory cytokines (TNF, IL-1, IL-6, or IL-17) when compared to their non-osteoporotic counterparts [20].”
Oxidative stress and inflammation: roles in osteoporosis
Luo, J. W., Li, L., Shi, W., Xu, K., Shen, Y., & Dai, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1611932 · Cited by 184
“It is unknown, yet, how IL-17 directly affects osteoclasts.”
InfluentialCline-Smith, A., Axelbaum, A., Shashkova, E., Chakraborty, M., Sanford, J., Panesar, P., Peterson, M., Cox, L., Baldan, A., Veis, D., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3966 · Cited by 108
“IL-17A, postmenopausal osteoporotic women have detectable levels of IL-17A in peripheral blood.((30)) Together, these results”
BackgroundDar, H. Y., Pal, S., Shukla, P., Mishra, P. K., Tomar, G. B., Chattopadhyay, N., & Srivastava, R. K. (2018) · Nutrition · doi:10.1016/j.nut.2018.02.013 · Cited by 108
Postmenopausal osteoporosis in rheumatoid arthritis: The estrogen deficiency-immune mechanisms link
Sapir‐Koren, R., & Livshits, G. (2017) · Bone · doi:10.1016/j.bone.2017.06.020 · Cited by 105
Probiotics ameliorate alveolar bone loss by regulating gut microbiota
Jia, L., Tu, Y., Jia, X., Du, Q., Zheng, X. M., Yuan, Q., Zheng, L., Zhou, X., & Xu, X. (2021) · Cell Proliferation · doi:10.1111/cpr.13075 · Cited by 86
Bhadricha, H., Patel, V. V., Singh, A. K., Savardekar, L., Patil, A. D., Surve, S. V., & Desai, M. P. (2021) · Scientific Reports · doi:10.1038/s41598-021-95640-0 · Cited by 82
Interleukin-17A Interweaves the Skeletal and Immune Systems
Tang, M., Lu, L., & Yu, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.625034 · Cited by 86
Chi, G., Qiu, L., Ma, J., Wu, W., & Zhang, Y. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-023-04179-5 · Cited by 58
The Interrelationship Between Diabetes, IL-17 and Bone Loss
Huang, Z., Pei, X., & Graves, D. T. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00559-6 · Cited by 56
Unraveling the molecular and immunological landscape: Exploring signaling pathways in osteoporosis
Amroodi, M. N., Maghsoudloo, M., Amiri, S., Mokhtari, K., Mohseni, P., Pourmarjani, A., Jamali, B., Khosroshahi, E. M., Asadi, S., Tabrizian, P., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116954 · Cited by 43
Osteoporosis: molecular pathogenesis and therapeutic interventions
Zhang, X., Liang, Y., Zhang, F., & Liu, X. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00349-5 · Cited by 44
Osteoimmunology: Crosstalk Between T Cells and Osteoclasts in Osteoporosis
Lu, Z., Xiao, P., Liu, S., Huang, C., Li, W., Mao, Y., Xu, Y., & Tian, Y. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09046-1 · Cited by 34
Hand tendinopathy risk factors in Taiwan: A population-based cohort study
Shen, P., Chang, P.-C., Jou, I., Chen, C., Lee, F., & Hsieh, J. (2019) · Medicine · doi:10.1097/md.0000000000013795 · Cited by 41
“Estrogen deficiency also upregulates T cell-mediated osteoclast activation and leads to osteoporosis.([25]) Hormone regulates the immune response might occur during the pathogenesis of these three hand tendinopathies.”
Ullah, A., Chen, Y., Singla, R. K., Cao, D., & Shen, B. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102505 · Cited by 33
Bone Marrow Adipose Tissue as a Critical Regulator of Postmenopausal Osteoporosis - A Concise Review
Niu, H., Zhou, M., Xu, X., & Xu, X. (2024) · Clinical Interventions in Aging · doi:10.2147/cia.s466446 · Cited by 21
“21,22 These inflammatory factors stimulate T cells, B cells, stromal cells and osteoblasts to produce RANKL and M-CSF.”
BackgroundWang, X., Zhang, X., Han, Y., Duan, X., Wang, J., Yan, H., Wang, S.-S., Xu, Y., Zhu, Z., Wang, L., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.876067 · Cited by 109
Self-citationLi, C., Liu, Y., Deng, M., Li, J., Li, S., Li, X., Zuo, Y., Shen, C., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349199 · Cited by 19
Pulsed low-dose RANKL as a potential therapeutic for postmenopausal osteoporosis
Cline-Smith, A., Gibbs, J., Shashkova, E. V., Buchwald, Z. S., & Aurora, R. (2016) · JCI Insight · doi:10.1172/jci.insight.88839 · Cited by 15
“These T cells producing TNFα, IL-6, and IL-17A have been observed in postmenopausal osteoporotic women (47) and may contribute to other comorbidities such as mood disorders, joint pain, and atherosclerosis observed in postmenopausal women.”
BackgroundLedoux, C., Boaretti, D., Sachan, A., Müller, R., & Collins, C. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.901720 · Cited by 9
“total) detected by a given assay was not always directly reported (Anastasilakis et al., 2008a; Molnár et al., 2014; Zhao et al., 2016), necessitating further investigation and assessment of manufacturer guidelines for individual assays.”
InfluentialBhadricha, H., Patel, V. V., Patil, A. D., Surve, S. V., & Desai, M. P. (2022) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2022.102702 · Cited by 8
Role of odanacatib in reducing bone loss due to endodontic disease: An overview
Bahuguna, R., Jain, A., Khan, S. A., & Arvind, M. S. (2016) · Journal of International Society of Preventive and Community Dentistry · doi:10.4103/2231-0762.197183 · Cited by 7
“2 Zhao et al.[4] 2016 In‐vitro study TNF helps in the production of chemokines.”
BackgroundInfluentialSims, N. A., & Lorenzo, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00050-6 · Cited by 7
Škubica, P., Hoffmanová, I., & Daňková, P. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.109871 · Cited by 6
Lu, L., Wen, Q., Zhang, X., Lv, J., Zhang, L., Liu, L., Yu, X., & Li, N. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062677 · Cited by 6
The Role of Immune Microenvironment in Maxillofacial Bone Homeostasis
Li, N., Fu, L., Li, Z., Ke, Y., Wang, Y., Wu, J., & Yu, J. (2021) · Frontiers in Dental Medicine · doi:10.3389/fdmed.2021.780973 · Cited by 8
“IL-17 can stimulate osteoclastic bone resorption, suppress bone formation, and result in bone loss in osteoporosis (113, 114).”
BackgroundZhang, P., Lin, L., Wang, N., Wang, Y., Miao, Y., Fei, J., & Hu, Q. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2529576 · Cited by 8
“Recent studies have shown that circulating IL-17 levels are significantly elevated in both postmenopausal women and ovariectomized (OVX) mice [16–18], suggesting that Th17 and its secreted cytokine IL-17 may play an important role in osteoporosis.”
Li, Y., Ng, S., Kong, K., Jin, M., Fan, W., Zhou, W., Zhai, Z., & Li, H. (2026) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.101044 · Cited by 7
Xiao, Z., Feng, C., Xu, C., Zhu, C., Chen, Q., Li, Q., Liu, L., Li, X., Zhu, X., Song, Y., et al. (2026) · Advanced Materials · doi:10.1002/adma.72909 · Cited by 6
Evolution and History of Osteoimmunology
Pietschmann, P., Föger‐Samwald, U., Butylina, M., & Sipos, W. (2021) · Osteologie/Osteology · doi:10.1055/a-1561-3426 · Cited by 3
Serum interleukin-17 and estradiol levels in postmenopausal women in relation to osteoporosis
El‐Mallah, R., Saab, A. A. R., & Nassar, N. M. (2021) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-021-00083-0 · Cited by 3
“[19] reported higher serum concentrations of IL-17, with increased IL17-producing CD4+ T cells, as well as mRNA levels of IL17 in CD4+ T cells in osteoporotic postmenopausal women than postmenopausal healthy controls.”
BackgroundYin, Q., Li, K., Chen, R., Li, X., Lo, W. L. A., Yu, Q., Ding, M., Zhang, S., & Wang, C. (2025) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s518164 · Cited by 2
Sun, Y., Xu, C., Ouyang, M., & Han, Y. (2025) · Rheumatology & autoimmunity · doi:10.1002/rai2.70020 · Cited by 2
Cytokine levels in postmenopausal women depending on IL-6, TNFSF11 and TNFRSF11B genes polymorphisms
Maylyan, E. A. (2018) · Актуальные проблемы медицины · doi:10.18413/2075-4728-2018-41-2-235-244 · Cited by 2
Association of Immune Cell Subsets with Incident Hip Fracture: The Cardiovascular Health Study
Elam, R. E., Bůžková, P., Delaney, J. A., Fink, H. A., Barzilay, J. I., Carbone, L. D., Saha, R., Robbins, J. A., Mukamal, K. J., Valderrábano, R. J., et al. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01126-8 · Cited by 2
“In several small, cross-sectional studies in postmenopausal women, levels of various circulating B and T lymphocyte subsets, including higher levels of Th17 cells, have been associated with lower bone mineral density (BMD) [18–20].”
BackgroundResultPan-immune inflammatory value a new diagnostic biomarker in postmenopausal osteoporosis
Başaran, P. Ö., & Tutan, D. (2024) · Journal of Medicine and Palliative Care · doi:10.47582/jompac.1447017 · Cited by 2
Jiba, U., Adil, M., Rafiya, K., Hasan, N., Ahmad, F. J., & Amin, S. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107470 · Cited by 2
Osteoporosis: A Multifactorial Disease
Wu, D., Cline-Smith, A., Shashkova, E. V., & Aurora, R. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97549 · Cited by 3
Putri, G., Jamil, N. S. N. A., Epsilawati, L., Sitam, S., Lita, Y. A., & Nursin, R. (2025) · Padjadjaran Journal of Dentistry · doi:10.24198/pjd.vol37no1.59209 · Cited by 1
Wang, X., Xiao, X., Situ, J., Xu, Q., Zhang, J., Xu, W., You, D., Ju, Y., Zhou, Y., Jiang, J., et al. (2025) · Medicine · doi:10.1097/md.0000000000045869 · Cited by 1
“For example, Zhao et al (2016) demonstrated that postmenopausal women with OP exhibit increased levels of pro-inflammatory cytokines, such as TNF, IL-1, IL-6, and IL-17, [29] supporting the relationship between bone immunology and OP.”
Self-citationGong, Y., Zeng, W., Liao, Y., Xie, X., Qin, Z., Li, C., & Zhang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1926935 · Cited by 1
ЦИТОКИНОВЫЙ СТАТУС ЖЕНЩИН С ПОСТМЕНОПАУЗАЛЬНЫМ ОСТЕОПОРОЗОМ В ДИНАМИКЕ ЛЕЧЕНИЯ АЛЕНДРОНАТОМ
Майлян, Э. А., Чурилов, А. В., Немсадзе, И. Г., Румянцева, З. С., & Сергеевич, Г. И. (2021) · CyberLeninK (CyberLeninka)
Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)
Velts, N. Y., Velts, O. V., & Alyautdin, R. N. (2024) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2024-12-2-190-200
Delgado, C. A., Lopes, F. F., Faverzani, J. L., Ribas, G. S., Marchetti, D. P., de Souza, C. F. M., Giugliani, R., Baldo, G., & Vargas, C. R. (2024) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2024.110834
Gelles, K., Kurz, V., Butylina, M., Wahl‐Figlash, K., Schepelmann, M., Meshcheryakova, A., & Pietschmann, P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27115047
“In line with this, D’Amelio et al. linked estrogen deficiency to enhanced osteoclastogenesis through increased production of TNF α and RANKL, while Zhao et al. found higher circulating levels of IL-17, IL-6, TNF α , and OPG in osteoporotic postmenopausal women than in controls [38,39].”
Nutrition in Osteoporosis: Prevention and Management
Khan, S., Parab, B., & Hasan, S. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1012585
General View of Arachidonic Acid (AA) Metabolism
Das, U. N. (2026) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/978-981-92-5964-9_3
Metadata
- Authors
- Zhao, R., Wang, X., & Feng, F.
- Affiliations
- Zhejiang Normal University (CN)
- ORCID
- Zhao, Renqing
- Venue
- Annals of Nutrition and Metabolism
- Publisher
- S. Karger AG
- Published
- 2016
- Volume
- 68
- Issue
- 2
- Pages
- 113-118
- ISSN
- 0250-6807 (ISSN-L)
- 1421-9697
- OpenAlex
- W2290918810
- Cited by
- 51
- References
- 28
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 8 · 2023: 4 · 2022: 4 · 2021: 8 · 2020: 4 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 2
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Annals of Nutrition and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- IL-17, CD4+ T cells, postmenopausal osteoporosis, bone loss, RORγt, TNF-α, RANKL, osteoprotegerin, interleukin-6, bone remodeling, cytokines, postmenopausal women, bone mineral density, mRNA expression, serum cytokines
- MeSH terms
- Aged, Female, Humans, Middle Aged, Tumor Necrosis Factor-alpha, CD4-Positive T-Lymphocytes, Bone Density, Osteoporosis, Postmenopausal, Up-Regulation, Cytokines, Postmenopause, Interleukin-17, Asian People, Osteoprotegerin, RANK Ligand, Nuclear Receptor Subfamily 1, Group F, Member 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.